On the other hand, BDNF has been reported to stimulate receptor activator of nuclear factor kappa B ligand (RANKL) production from osteoblasts (OBs), thereby contributing to the formation of osteolytic bone lesions from multiple myeloma [21, 22]. This evidence concerns the gene TNFSF11 and plasma cell myeloma.